For open-angle glaucoma or ocular hypertension. ANDA 76260, held by Bausch And Lomb Inc. Brimonidine Tartrate.
As of Nov 16, 2026, ANDA 76260 (Brimonidine Tartrate), held by Bausch And Lomb Inc, was first approved by FDA on May 28, 2003, with 0 approved supplements and 0 published complete response letters.
Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 28, 2003 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Brimonidine Tartrate0.2% · solution/drops;ophthalmic | Brimonidine Tartrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters